The diagnostic approach to hepatocellular carcinoma;Diagnostik des hepatozellulären Karzinoms

Zeitschrift fur Gastroenterologie

Volumn 45, Issue 10, 2007, Pages 1067-1074

  Schacherer, Doris ^a,b   Schoelmerich, J ^a   Zuber Jerger, I ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Diagnostics; HCC; Liver

Indexed keywords

ALPHA FETOPROTEIN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; ECHOGRAPHY; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOFREQUENCY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; ULTRASOUND;

CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC;

EID: 36049042234     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-963354     Document Type: Review

References (49)

1. Bosch FX, Ribes J, Diaz M et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: 5-16
2. Tangkijvanich P, Mahachai V, Suwangool P et al. Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma. World J Gastroenterol 2004; 10:1547-1550
3. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35: 421-430
4. Giordano TP, Kramer JR, Souchek J et al. Cirrhosis and heptatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med 2004; 164: 2349-2354
5. Gish RG. Hepatocellular carcinoma: overcoming challenges in disease management. Clin Gastroenterol Hepatol 2006; 4: 252-261
6. Llovet JM. Hepatocellular carcinoma: patients with increasing alpha-fetoprotein but no mass on ultrasound. Clin Gastroenterol Hepatol 2006; 4: 29-35
7. Farinati F, Marino D, De Giorgio M et al. Diagnostic and prognostic role of α-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006; 101: 524-532
8. Daniele B, Bencivenga A, Megna AS et al. α-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004; 127: 108-112
9. Pateron D, Ganne N, Trinchet JC et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis, J Hepatol 1994; 20: 65-71
10. Peterson MS, Baron RL. Radiologic diagnosis of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 123-144
11. Liu WC, Lim JH, Park CK et al. Poor sensitivity of sonography in detection of hepatocellular carcinoma in advanced liver cirrhosis: accuracy of pretransplantation sonography in 118 patients. Eur Radiol 2003; 13: 1693-1698
12. Zhang BH, Yang BH. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen 1999; 6: 108-110
13. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422
14. Trevisani F, De NS, Rapaccini G et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002; 97: 734-744
15. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology2005; 42: 1208-1236
16. Lencioni R, Cioni D, Delia Pina C et al. Imaging diagnosis. Semin Liver Dis 2005; 2: 162-170
17. Lencioni R, Pinto F, Armillotta N et al. Assessment of tumor vascularity in hepatocellular carcinoma: comparison of power Doppler US and color Doppler US. Radiology 1996; 201: 353-358
18. Rickes S, Schulze S, Neye H et al. Improved diagnosing of small hepatocellular carcinomas by echo-enhanced power Doppler sonography in patients with cirrhosis. Eur J Gastroenterol Hepatol 2003; 15: 893-900
19. Tanaka S, Ioka T, Oshikawa O et al. Dynamic sonography of hepatic tumors. AJR Am J Roentgenol 2001; 177: 799-805
20. th United European Gastroenterology Week, Copenhagen 2005
21. Quaida E, Calliada F, Bertolotto M et al. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology 2004; 232: 420-430
22. Gaiani S, Celli N, Piscaglia F et al. Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J Hepatol 2004; 41: 421-426
23. Rickes S, Ocran K, Schulze S et al. Evaluation of Doppler sonographic criteria for the differentiation of hepatocellular carcinomas and regenerative nodules in patients with liver cirrhosis. Ultraschall Med 2002; 23: 83-90
24. Bhartia B, Ward J, Guthrie JA et al. Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. Am J Roentgenol 2003; 180: 577-584
25. Lutz AM, Willmann JK, Goepfert K et al. Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and super-paramagnetic iron oxide-enhanced T1-weighted MR imaging. Radiology 2005; 237: 520-528
26. Kim YK, Kwak HS, Kim CS et al. Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT. Radiology 2006; 238: 531-541
27. Stoker J, Romijn MG, de Man RA et al. Prospective comparative study of spiral computer tomography and magnetic resonance imaging for detection off hepatocellular carcinoma. Gut 2002; 51: 105-107
28. Colli A, Fraquelli M, Casazza G et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systemic review. Am J Gastroenterol 2006; 101: 513-523
29. Caturelli E, Solmi L, Anti M et al. Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Gut 2004; 53: 1356-1362
30. Caturelli E, Biasini E, Bartolucci F et al. Diagnosis of hepatocellular carcinoma complicating liver cirrhosis: utility of repeat ultrasound-guided biospy after unsuccessful first sampling. Cardiovasc Intervent Radiol 2002; 25: 295-299
31. Bolondi L, Benzi G, Santi V et al. Relationship between alpha-fetoprotein serum levels, tumour volume and growth rate of hepatocellular carcinoma in a western population. Ital J Gastroenterol 1990; 22: 190-194
32. Toyoda H, Kumada T, Kiriyama S et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006; 4: 111-117
33. Koike Y, Shiratori Y, Sato S et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91: 561-569
34. Yan P, Yan LN. Staging of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2003; 2: 491-495
35. Marrero JA, Fontana RJ, Barrat A et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an american cohort. Hepatology 2005; 41: 707-716
36. Bigourdan JM, Jaeck D, Meyer N et al. Small hepatocellular carcinoma in Child A cirrhotic patients: hepatic resection versus transplantation. Liver Transpl 2003; 9: 513-520
37. Giangregorio F, Aragona G, Marinone M et al. Clinical utility of contrast-enhanced US (CEUS) for the control of loco-regional treatments of HCCs. Poster Presentation 13th United European Gastroenterology Week, Copenhagen 2005
38. Pompili M, Mirante VG, Rondinara G et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficiacy at explant analysis and of safety for tumor recurrence. Liver Transplant 2005; 9: 1117-1126
39. Chen YK, Hsieh DS, Liao CS et al. Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. Anticancer Res 2005; 25: 4719-4725
40. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liv Dis 1999; 19: 311-322
41. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699
42. Yao FY, Hirose R, LaBerge JM et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transplant 2005; 12: 1505-1514
43. Peterson MS, Baron RL, Marsh JW Jr et al. Pretransplantation surveillance for possible hepatocellular carcinoma in patients with cirrhosis: epidemiology and CT-based tumor detection rate in 430 cases with surgical pathologic correlation. Radiology 2000; 217: 743-749
44. Maciel AC, Cerski CT, Moreira RK et al. Hepatocellular carcinoma in patients undergoing orthothopic liver transplantation: radiological findings with anatomopathological correlation in Brazil. Arq Gastroenterol 2006; 43: 24-29
45. Rode A, Bancel B, Douek P et al. Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 2001; 25: 327-336
46. de Ledinghen V, Laharie D, Lecesne R et al. Detection of nodules in liver cirrhosis: spiral computed tomograpy or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. Eur J Gastroenterol Hepatol 2002; 14: 159-165
47. Libbrecht L, Bielen D, Verslype C et al. Focal lesions in cirrhotic expiant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transp 2002; 8: 749-761
48. Macarini L, Marini S, Milillo P et al. Double-contrast MRI (DC-MRI) in the study of the cirrhotic liver: utility of administering Gd-DTPA as a complement to examinations in which SPIO liver uptake and distribution alterations (SPIO-LUDA) are present and in the identification and characterisation of focal lesions. Radiol Med (Torino) 2006; 111: 1087-1102
49. Ruelas-Villavicencio AL, Vargas-Vorackova F. In whom, how and how often is surveillance for hepatocellular carcinoma cost-effective? Ann Hepatol 2004; 3: 152-159